Niagen Bioscience, Inc.
About Niagen Bioscience, Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $129.4M
- Net income
- $17.4M
- Total assets
- $106.4M
- Market cap
- $274.8M
- Gross margin
- 64.3%
- Operating margin
- 12.6%
- Net margin
- 13.4%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $129.4M
- Cost of revenue
- $46.2M
- Gross profit
- $83.2M
- Operating expenses
- $66.9M
- Operating income
- $16.3M
- Income tax
- $810.0K
- Net income
- $17.4M
- EPS (basic)
- $0.22
- EPS (diluted)
- $0.20
Balance sheet
- Total assets
- $106.4M
- Current assets
- $96.8M
- Total liabilities
- $29.9M
- Current liabilities
- $19.9M
- Shareholders’ equity
- $76.5M
Cash flow
- Operating cash flow
- $13.5M
- Investing cash flow
- -$292.0K
- Financing cash flow
- $6.9M
- Net cash flow
- $20.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $274.8M
- P/E ratio
- 16.8
- EPS (diluted)
- $0.2
- Shares outstanding
- 81.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 24, 2008
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $17.4M in FY2025.
- Gross margin of 64.3%, net margin 13.4%.
- Trading 77% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 16.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Niagen Bioscience, Inc..
Write a review
News about Niagen Bioscience, Inc.
News & sentiment via Polygon.io
